Targeting fatty acid synthase in preclinical models of TNBC brain metastases synergizes with SN-38 and impairs invasion
Habib Serhan, Liwei Bao, Cheng Xu, Zhaoping Qin, Chia‐Jen Liu, Jason Heth, Aaron M. Udager, Matthew B. Soellner, Sofía D. Merajver, Aki Morikawa, Nathan Merrill
Abstract
Fatty acid synthesis (FAS) has been shown to play a key role in the survival of brain-metastatic (BM) breast cancer. We demonstrate that the fatty acid synthase inhibitor TVB-2640 synergizes with the topoisomerase inhibitor SN-38 in triple-negative breast cancer (TNBC) BM cell lines, upregulates FAS and downregulates cell cycle progression gene expression, and slows the motility of TNBC BM cell lines. The combination of SN-38 and TVB-2640 warrants further consideration as a potential therapeutic option in TNBC BMs.
Topics & Concepts
Fatty acid synthaseTriple-negative breast cancerCancer researchMotilityBiologyFatty acidFatty acid synthesisCell cultureBreast cancerCancerChemistryMedicineInternal medicineBiochemistryCell biologyGeneticsCancer, Lipids, and MetabolismLung Cancer Treatments and MutationsRNA modifications and cancer